It has been successful in expanding the coverage of new drug

The MOHW, self-evaluation of major policies last year, DUR prevents damage to Ranitidine impurities

Major achievements of the Medical Device Industry Promotion Act

It was evaluated that the government has achieved success in strengthening generic management, such as strengthening guarantees like new drugs for anticancer and rare diseases last year, and announcing plans to revise the generic drug pricing system.

 

In the case of Ranitidine, a gastrointestinal drug containing carcinogenic substance NDMA, it was also diagnosed that DUR information system prevented further damage such as pre-blocking prescriptions and dispensing and shortening recovery procedures.

 

The MOHW said in a report on the results of the self-evaluation of major policies in 2019.

 

According to the report on the 22nd, the MOHW first gave a rating of 'slightly insufficient' for policy to advance drug distribution structure, 'regular' for strengthening insurance drug coverage and appropriate management policy for drug costs, and 'moderate' for policy strengthening pharmaceutical, medical device, and cosmetics industry competitiveness.

 

◆Advancement of drug distribution structure = Specifically, in the case of the policy of advancing drug distribution structure, it was mentioned that DUR information system and drug distribution information system were used to block prescribing and dispensing Ranitidine prescriptions and to shorten the recovery process.

 

It was considered that the improvement and supplementation needs to actively collect patient and consumer opinions and develop performance indicators that will specifically include the results of the advancement of the drug distribution structure.

 

In particular, it is said that performance indicators are needed to evaluate the advancement of the distribution structure of safety-related drugs.

 

The intention is that there are no indicators that can actually represent the advancement of the distribution structure of safe medicines.

 

In addition, the MOHW also considered that the rebate structure of pharmacies and hospitals was needed as a way to investigate the reality of the development of a dedicated pharmacy into hospital admission fees and cash rebates.

 

It is not only to limit rebates between wholesalers and hospitals, but also to establish a rebate investigation method for the number of prescriptions between hospitals and pharmacies.

 

◆Enhancement of insurance drug coverage and appropriate management of drug costs = The MOHW evaluated that it has achieved enhanced security, such as new drugs for anticancer and rare diseases, which have high social demands and high medical expenses.

 

Strengthening generic management by announcing plans to reorganize the generic drug pricing system was also a major achievement.

 

However, the MOHW said there was a need to further increase the goal for policy enhancement and reducing drug costs.

 

The MOHW says that a reduction in the proportion of drug costs may be a natural decrease as the overall rate of increase in health care increases, so it sets more aggressive goals.

 

The MOHW said that in order to properly manage the drug cost, it is necessary to take various measures, such as managing generic drug prices, improving the irrational distribution structure of hospitals, and managing rational drug use.

 

The ratio of drug costs was decided by the contents suggested by the evaluators, but it was necessary to raise the target.

 

In terms of suitability for on-site monitoring and response to changes in the situation, the rapid response to NDMA detection was highly appreciated.

 

It was diagnosed that the new drug listing guarantees were strengthened and the goals were achieved.

 

◆Strengthening competitiveness in the pharmaceutical and medical device industry = the MOHW cited strengthening competitiveness as enacting the 'Medical Device Industry Fostering and Innovative Medical Device Support Act', nurturing professional manpower, and opening AI new drug development support centers.

 

However, it is said that it is necessary to strengthen the qualitative performance indicators based on the pharmaceutical and medical device industries.

 

The MOHW said that the pharmaceutical and medical device industry is a higher value-added business and has high future-oriented importance.

 

It was said that the expert networking was also excellent, so that the opinion gathering was appropriate when carrying out the policy.

 

Furthermore, although the achievement index of the policy to strengthen the competitiveness of the pharmaceutical and medical device industry was achieved, it was evaluated that it was evaluated that it was not the promotion effect of last year alone.

 

In addition, the overseas market expansion and the national recognition of the nation's technological power were raised, and the HOHW's leadership in the medical device industry across the government was highly appreciated.